Table 3.
Systemic pharmacological treatment for psoriasis and psoriatic arthritis
| Type of systemic treatment | Baseline*
|
Follow-up**
|
||
|---|---|---|---|---|
| Males N (%) | Females N (%) | Males N (%) | Females N (%) | |
| Cyclosporine | 58 (47.9) | 52 (50.0) | 52 (43.0) | 42 (40.4) |
| Cyclosporine + methotrexate | 17 (14.0) | 19 (18.3) | 19 (15.7) | 15 (14.4) |
| Cyclosporine + biologics | 16 (13.2) | 7 (6.7) | 24 (19.8) | 21 (20.2) |
| Cyclosporine + other | 24 (19.8) | 21 (20.2) | 16 (13.2) | 17 (16.3) |
| Other, not specified | 6 (5.0) | 5 (4.8) | 10 (8.3) | 9 (8.7) |
Notes:
*
At baseline, treatment assumed during the last 12 months were recorded;
**
follow-up refers to the 12th month of study observation period. Other drugs include NSAIDs, corticosteroids, sulfasalazine, retinoids, etc.
Abbreviation: NSAIDS, non-steroidal anti-inflammatory drugs.